Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

LBBAP limits hospital readmissions after TAVR
Left bundle branch area pacing is associated with better long-term outcomes than traditional right ventricular pacing when patients require PPMI after TAVR, according to new research in Heart Rhythm.
FDA approves Boston Scientific leads for left bundle branch area pacing
Boston Scientific's INGEVITY+ pacing leads were originally approved by the FDA back in 2019. They can now be used for LBBAP, a new alternative to biventricular pacing.
JACC editor excited by progress during a 'very important moment' for cardiology
Harlan Krumholz, MD, editor-in-chief of the Journal of the American College of Cardiology, explains some of the key technology and treatment trends he has his eyes on.
FDA approves Biotronik lead, catheter for left bundle branch area pacing
LBBAP is a relatively new alternative to biventricular pacing. The FDA's decision was based largely on data from the BIO-CONDUCT clinical trial.
Surgeons make history, perform world’s first fully robotic heart transplant
The procedure, which lasted roughly two and half hours, was performed on a 16-year-old patient with end-stage heart failure.

American Heart Association introduces new certification program for home health heart failure patients

Heart failure cases are expected to keep growing in the years ahead.

October 22, 2021

Omecamtiv mecarbil may provide value for patients with severe heart failure

The analysis supports a potential role for omecamtiv mecarbil in the treatment of severe HF.

October 14, 2021

Exposure to air pollution, traffic noise raises odds of heart failure

The study examined the impact of long-term environmental exposure to air pollution and vehicle noise.

October 6, 2021

Heart failure patients benefit from rehabilitation intervention

Older patients hospitalized with heart failure, acute decompensated HF and preserved ejection fraction had poor baseline functionality, quality of life and depression.

October 5, 2021

COVID-era telephone visits confer higher 90-day mortality risk for HF patients

According to a new analysis, the widespread use of remote heart failure care during the pandemic may lead to increased telemedicine use in the future.

October 4, 2021